Royal Bank Of Canada Issues Positive Forecast for CorMedix (NASDAQ:CRMD) Stock Price

CorMedix (NASDAQ:CRMD) had its price target lifted by research analysts at Royal Bank Of Canada from $13.00 to $14.00 in a report released on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 81.11% from the stock’s current price.

A number of other research analysts have also commented on CRMD. Needham & Company LLC lifted their price objective on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Citizens Jmp reaffirmed a “market outperform” rating and set a $19.00 price objective on shares of CorMedix in a research note on Tuesday, April 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a research report on Tuesday. Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Finally, Leerink Partners upped their price target on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.00.

CorMedix Stock Performance

Shares of CRMD stock traded down $0.41 during trading hours on Friday, hitting $7.73. The stock had a trading volume of 857,616 shares, compared to its average volume of 1,724,248. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.97 and a quick ratio of 2.74. The firm has a market capitalization of $606.42 million, a PE ratio of 3.65 and a beta of 1.50. The stock’s 50 day moving average is $8.16 and its 200 day moving average is $7.65. CorMedix has a twelve month low of $6.13 and a twelve month high of $14.96.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, August 13th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. The business had revenue of $101.93 million for the quarter, compared to analysts’ expectations of $96.04 million. As a group, research analysts forecast that CorMedix will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CorMedix

A number of hedge funds and other institutional investors have recently modified their holdings of CRMD. Financial Management Professionals Inc. acquired a new position in shares of CorMedix in the fourth quarter valued at approximately $25,000. Comerica Bank raised its position in shares of CorMedix by 454.6% in the 3rd quarter. Comerica Bank now owns 2,690 shares of the company’s stock worth $31,000 after buying an additional 2,205 shares during the period. Canada Pension Plan Investment Board acquired a new position in CorMedix in the second quarter valued at $42,000. Kestra Advisory Services LLC acquired a new position in CorMedix in the fourth quarter valued at $49,000. Finally, Caitong International Asset Management Co. Ltd grew its position in CorMedix by 666.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock valued at $51,000 after acquiring an additional 3,813 shares during the period. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

Key CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix reported Q2 revenue of $101.9 million, above the roughly $96 million analyst consensus, while adjusted EBITDA reached $58.7 million and net income was $26.0 million. EPS of $0.29 also exceeded expectations. Growth was supported by continued DefenCath utilization and contributions from the Melinta portfolio. CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
• Positive Sentiment: Management maintained its FY 2026 revenue outlook of $325 million to $345 million and raised adjusted EBITDA guidance, reinforcing expectations for strong profitability and operating leverage. CorMedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company expects to submit a supplemental filing for its fungal-disease treatment by the third quarter. Progress on this regulatory opportunity could provide an additional growth catalyst beyond DefenCath. CorMedix CEO expects supplemental filing for fungal disease treatment by Q3
• Neutral Sentiment: Brokerages currently assign CorMedix an average “Moderate Buy” recommendation, indicating generally favorable sentiment but not a uniformly bullish analyst view. CorMedix Given Average Recommendation of Moderate Buy
• Neutral Sentiment: Although the revenue outlook’s midpoint is broadly in line with consensus, investors may be taking profits or reassessing valuation after the initial earnings-driven rally. The stock remains below its 50-day moving average, adding to near-term volatility.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.